先健科技(01302.HK)：IBS可吸收药物洗脱冠脉支架系统公布II期临床研究及III期临床研究两年随访结果

Core Viewpoint - The company, Xianjian Technology (01302.HK), has successfully completed the two-year follow-up of Phase II and Phase III clinical studies for its self-developed IBS® absorbable drug-eluting coronary stent system, with results to be presented at the TCT 2025 conference [1] Group 1 - The IBS® coronary stent has completed two-year follow-ups for both Phase II and Phase III clinical studies [1] - The results will be presented by Professor Song Lei from the Chinese Academy of Medical Sciences at the TCT 2025 conference held on October 26-27, 2025 [1] - The studies include major endpoint imaging follow-up results from the Phase II clinical study and clinical endpoint follow-up results from the Phase III clinical study [1]